Invivo: Bruker Acquires InVivo Biotech Services

Bruker said today it has acquired InVivo Biotech Services for an undisclosed price, in a deal designed to expand its expertise and infrastructure for consumables development, validation and production. Bruker said the acquisition will also support its strategy of expanding its microbiology assay menu for the MALDI Biotyper platform-while InVivo's kit development and production capabilities are expected to shorten time to market for such new assays. InVivo's expertise in monoclonal antibodies, Bruker added, opens new possibilities to combine the specificity of antibody enrichment with the multi-channel information read-out via MALDI Biotyper. Antibody enrichment strategies applied before MALDI Biotyper analysis could further shorten microbial cultivation and time to result, Bruker reasons. The buyer added that InVivo's capabilities will support its activities in translational pathology research with the MALDI Tissuetyper platform. Enzymes involved in the digestion and sample preparation of formalin-fixed-paraffin-embedded (FFPE) tissue are expected to complement MALDI Tissuetyper, ...